08.05.2018
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler Q1/2018: Sales increase of 9%; earnings remain below average
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Quarter Results
Eckert & Ziegler Q1/2018: Sales increase of 9%; earnings remain below
average
08.05.2018 / 07:45
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 8 May 2018. Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related
applications in medicine, science and industry, increased its sales from
continuing operations in the first quarter 2018 by 9 % year on year to EUR
35.7 million. Earnings per share decreased by EUR 0.15 to EUR 0.44. This is
primarily the result of temporary weak earnings in the Isotope Products
segment that can be traced back to phasing effects.
Nevertheless, the Isotope Products segment - which increased its sales by
EUR 2.9 million or 14 % to EUR 24 million due to the sales of the
Gamma-Service Group newly acquired at the end of May 2017 - experienced the
largest growth spurt within the continuing operations. Sales in the
Radiation Therapy segment rose as well by EUR 0.7 million or 12 % to EUR 6.8
million, driven by the sales of WOLF Medizintechnik GmbH acquired in
January. The Radiopharma segment sales remained at the previous year's level
of EUR 6.6 million.
The strong euro had adverse effects on the sales growth in all segments due
to the adverse effects on foreign currency sales. Thus, compared with the
previous year, the Group lost EUR 2.5 million, so that the growth after
adjustment for currency effects would have totaled EUR 5.5 million or 17 %.
Organic, real sales growth - in other words, sales adjusted for currency
effects and excluding the acquisitions and disposals made in 2017 - amounted
to EUR 1.4 million.
As a result of the sale of the Cyclotron unit and the repayment of existing
loans as scheduled, the Eckert & Ziegler Group has only minor loan
liabilities. Net liquidity, in other words cash less bank liabilities,
amounts to EUR 51.9 million.
For the fiscal year 2018, net profit is expected to be at around EUR 2.20
per share and sales at around EUR 155 million, assuming that the euro
exchange rate does not exceed $ 1.15.
The complete financial statements can be viewed here:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz118e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700), with around 800 employees, is one of the world's largest
providers of isotope-related components for radiation therapy and nuclear
medicine.
Contributing to saving lives.
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de
---------------------------------------------------------------------------
08.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
683217 08.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ